Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × 64Cu-DOTATATE × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡